Stockreport

Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Rad...

Castle Biosciences, Inc. - Common stock  (CSTL) 
Last castle biosciences, inc. - common stock earnings: 3/10 04:05 pm Check Earnings Report
PDF expertise in cutaneous squamous cell carcinoma (SCC) management; they provide a recommended framework for using DecisionDx-SCC testing with American Joint Committee on C [Read more]